Objective: The aim of the study was to analyze the clinical characteristics of pediatric patients with ocular toxocariasis. Methods: Ocular toxocariasis was diagnosed and treated in 46 children from Shanghai and surrounding provinces. The diagnosis of ocular toxocariasis was confirmed immunologically by performing an enzyme-linked immunosorbent assay on serum and/or intraocular fluid. All pediatric patients and their guardians completed a questionnaire concerning their cases and living habits. Results: The mean age of onset was 6 ± 3 years. Most children (85%) resided in rural areas, and 91% of the children had contact with adult dogs or puppies. At the first visit, visual acuity (VA) was <20/200 in 36 cases, and we detected peripheral granuloma in 36 patients. In our study, the most common signs were vitritis, vitreous strands, and tractional retinal detachment. The Optomap 200Tx device detected granuloma with an 85% sensitivity, which is much higher than that of other techniques. We treated 40 cases (87%) with topical corticosteroids, while 28 patients (61%) were treated with systemic corticosteroids. Only 18 children (39%) required surgical intervention. All patients were examined and treated by the same ophthalmologists. Conclusions: Preschool children in China are more often affected by toxocariasis compared with other age groups. The most common signs included unilateral granuloma and ocular inflammation. In our study, clinical manifestations were severe and complicated. At the first visit, VA was <20/200 in most patients. Ocular toxocariasis was diagnosed on the basis of clinical signs and symptoms; the diagnosis was confirmed by immunological testing. Techniques using the Optomap 200Tx device can facilitate the early detection and lead to better visual prognosis.

Keywords:
Ocular toxocariasis, Optomap 200Tx, Clinical features, Toxocara canis antibodies
1.
Sabrosa NA, de Souza EC: Nematode infections of the eye: toxocariasis and diffuse unilateral subacute neuroretinitis. Curr Opin Ophthalmol 2001;12:450-454.
2.
Santarém VA, Franco Eda C, Kozuki FT, et al: Environmental contamination by Toxocara spp. eggs in a rural settlement in Brazil. Rev Inst Med Trop Sao Paulo 2008;50:279-281.
3.
Magnaval JF, Glickman LT, Dorchies P, et al: Highlights of human toxocariasis. Korean J Parasitol 2001;39:1-11.
4.
Taylor MRH, Holland C: Toxocariasis; in Gillespie SH, Pearson RD (eds): Principles and Practice of Clinical Parasitology. Chichester, Wiley, 2001, pp 501-522.
5.
Wilder HC: Nematode endophthalmitis. Trans Am Acad Ophthalmol Otolaryngol 1950;55:99-109.
6.
Arevalo JF, Espinoza JV, Arevalo FA: Ocular toxocariasis. J Pediatr Ophthalmol Strabismus 2013;50:76-86.
7.
Alba-Hurtado F, Muñoz-Guzmán MA, Valdivia-Anda G, et al: Toxocara canis: larval migration dynamics, detection of antibody reactivity to larval excretory-secretory antigens and clinical findings during experimental infection of gerbils (meriones unguiculatus). Exp Parasitol 2009;22:1-5.
8.
Elefant GR, Shimizu SH, Sanchez MC, et al: A serological follow-up of toxocariasis patients after chemotherapy based on the detection of IgG, IgA, and IgE antibodies by enzyme-linked immunosorbent assay. Clin Lab Anal 2006;20:164-172.
9.
Glickman LT, Schantz PM: Epidemiology and pathogenesis of zoonotic toxocariasis. Epidemiol Rev 1981;3:230-250.
10.
Yokoi K, Goto H, Sakai J, et al: Clinical features of ocular toxocariasis in Japan. Ocul Immunol Inflamm 2003;11:269-275.
11.
Mackenzie PJ, Russell M, Ma PE, et al: Sensitivity and specificity of the optos optomap for detecting peripheral retinal lesions. Retina 2007;27:1119-1124.
12.
Kang KB, Wessel MM, Tong J, et al: Ultra-widefield imaging for the management of pediatric retinal diseases. J Pediatr Ophthalmol Strabismus 2013;50:282-288.
13.
Kaines A, Oliver S, Reddy S, et al: Ultrawide angle angiography for the detection and management of diabetic retinopathy. Int Ophthalmol Clin 2009;49:53-59.
14.
do Lago A, Andrade R, Muccioli C, et al: Optical coherence tomography in presumed subretinal Toxocara granuloma: case report. Arq Bras Oftalmol 2006;69:403-405.
15.
Stewart JM, Cubillan LD, Cunningham ET Jr: Prevalence, clinical features, and causes of vision loss among patients with ocular toxocariasis. Retina 2005;25:1005-1013.
16.
Kwon SI, Lee JP, Park SP, et al: Ocular toxocariasis in Korea. Jpn J Ophthalmol 2001;55:143-147.
17.
Walker JC, Nicholas WL, Stewart AC: Diagnosis of ocular toxocariasis. Aust J Ophthalmol 1983;11:138-139.
18.
Shields JA: Ocular toxocariasis. A review. Surv Ophthalmol 1984;28:361-381.
19.
Wilkinson CP, Welch RB: Intraocular toxocara. Am J Ophthalmol 1971;71:921-930.
20.
Kimura SJ, Thygeson P, Hogan MJ: Signs and symptoms of uveitis: classification of the posterior manifestations of uveitis. Am J Ophthalmol 1959;47:71-76.
21.
Good B, Holland CV, Taylor MR, et al: Ocular toxocariasis in schoolchildren. Clin Infect Dis 2004;39:173-178.
22.
Pawlowski Z: Toxocariasis in humans: clinical expression and treatment dilemma. J Helminthol 2001;75:299-305.
23.
Zhou M, Chang Q, Gonzales JA, et al: Clinical characteristics of ocular toxocariasis in Eastern China. Graefes Arch Clin Exp Ophthalmol 2012;250:1373-1378.
24.
de Visser L, Rothova A, de Boer JH, et al: Diagnosis of ocular toxocariasis by establishing intraocular antibody production. Am J Ophthalmol 2008;145:369-374.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.